Acelyrin (SLRN) Stock Forecast & Price Target

$4.93

0.00 (0.00%)

(As of 09/30/2024 ET)

Acelyrin - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 6 Analyst Ratings

Sell
0

Hold
3

Buy
3

Based on 6 Wall Street analysts who have issued ratings for Acelyrin in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 3 have given a hold rating, and 3 have given a buy rating for SLRN.

Consensus Price Target

$10.83
119.74% Upside

According to the 6 analysts' twelve-month price targets for Acelyrin, the average price target is $10.83. The highest price target for SLRN is $20.00, while the lowest price target for SLRN is $6.00. The average price target represents a forecasted upside of 119.74% from the current price of $4.93.

Get the Latest News and Ratings for SLRN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Acelyrin and its competitors.

SLRN Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$10.83	$10.83	$12.80	$37.00
Forecasted Upside	119.74% Upside	126.64% Upside	208.43% Upside	278.71% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Moderate Buy

Does Elon Musk control the U.S. gov’t? (Ad)

Elon has been advising the government to reopen America’s nuclear facilities for years, and now, with the help of Biden’s ADVANCE act, these facilities are once again going back online just as he requested. One company is poised to benefit from America’s nuclear revival like no other. Elon Musk is one of the few people who knows this.

Watch this new documentary and you’ll discover what Elon knows,

SLRN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SLRN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Acelyrin Stock vs. The Competition

Type	Acelyrin	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	119.74% Upside	823.09% Upside	6.15% Upside
News Sentiment Rating	Positive News See Recent SLRN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/19/2024	Morgan Stanley 3 of 5 stars		Lower Target	Equal Weight ➝ Equal Weight	$13.00 ➝ $6.00	+47.78%
8/14/2024	Piper Sandler 2 of 5 stars		Lower Target	Overweight ➝ Overweight	$68.00 ➝ $20.00	+401.25%
8/14/2024	HC Wainwright 2 of 5 stars	E. Bodnar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$18.00 ➝ $6.00	+26.05%
7/8/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Archila Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$13.00 ➝ $13.00	+220.20%
12/8/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$8.00	+11.73%
11/28/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$15.00 ➝ $12.00	+100.00%
5/30/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:44 AM ET.

SLRN Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Acelyrin is $10.83, with a high forecast of $20.00 and a low forecast of $6.00.
: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acelyrin in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SLRN shares.
: According to analysts, Acelyrin's stock has a predicted upside of 119.74% based on their 12-month stock forecasts.
: Over the previous 90 days, Acelyrin's stock had 1 upgrade and 1 downgrade by analysts.
: Acelyrin has been rated by research analysts at HC Wainwright, Morgan Stanley, Piper Sandler, and Wells Fargo & Company in the past 90 days.
: Analysts like Acelyrin less than other "medical" companies. The consensus rating score for Acelyrin is 2.50 while the average consensus rating score for "medical" companies is 2.78. Learn more on how SLRN compares to other companies.